title: Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.
authors.forename: Håvard
authors.initials: H
authors.lastname: Søiland
authors.forename: Kari Britt
authors.initials: KB
authors.lastname: Hagen
authors.forename: Jennifer
authors.initials: J
authors.lastname: Gjerde
authors.forename: Tone Hoel
authors.initials: TH
authors.lastname: Lende
authors.forename: Ernst A
authors.initials: EA
authors.lastname: Lien
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D017024:Chemotherapy, Adjuvant; D015897:Comorbidity; D018572:Disease-Free Survival; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D013629:Tamoxifen